Saturday 17 October 2026
Export ACTU’s income statement to Excel — free account
Actuate Therapeutics, Inc.
ACTU Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 5.54%, each against the same quarter a year earlier.
0.61
0.11
+22.00%
Follow ACTU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 2,457.65% | 3,304.93% | (553.75%) | (296.04%) |
+8 more TTM periods Free account |
|
| (336.18%) | (321.58%) | (190.35%) | (150.86%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(2,169.70%) | (567.13%) | (280.07%) | (217.86%) | |
Free Cash Flow per Share |
(0.83) | (0.83) | (0.91) | (0.95) | |
Free Cash Flow |
(19.84) | (19.60) | (19.21) | (20.24) | |
| Other line items | |||||
Cash ROIC |
(366.32%) | (164.49%) | (91.10%) | (72.66%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,018.31) | (1,070.38) | (1,102.72) | (1,194.41) | |
Operating CF/Net income |
0.97 | 0.91 | 0.86 | 0.84 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.83) | (0.83) | (0.91) | (0.95) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates